Diabetic Foot
Conditions
Keywords
diabetic foot infections, antibiotic reduction, osteomyelitis, soft tissue infections
Brief summary
This is a randomized, unblinded, single-centre study. After eventual surgical debridement (not amputation), patients will be randomized to receive 1 of 2 targeted antibiotic regimens, in the ratio 1:1. For diabetic toe osteomyelitis, the patients will be randomized between a 3 and a 6 week's arm, for soft tissue infections between 10 and 20 days. The final assessments used in the primary efficacy analysis will be obtained at the test-of-cure (TOC) visit approximately 60 days after treatment is stopped.
Detailed description
Diabetic foot infections (DFI) are frequent and are associated with a high burden of morbidity, costs, recurrence risk or new episodes of infections. About two-third of recurrent DFI may reveal other microorganisms than in the previous period, suggesting new episodes of infection due to the underlying problem, and/or selection by prior antimicrobial therapy. Osteomyelitis in the diabetic toe is almost always established by contiguous spread of infection from a chronic ulcer. It occurs in up to 15% of patients with a diabetic foot ulcer and about 20% of all DFI (and over half of severe infections) involve bone at presentation. The severity of a diabetic foot infection is based on the local and systemic signs and symptoms of infection and has been categorically defined in the Infectious Disease Society of America guidelines for the Diagnosis and Treatment of Diabetic Foot Infections (IDSA guidelines). Knowing the potential for poor outcomes, many clinicians have tended to treat DFIs with a long duration of antibiotic therapy, with many side effects, development and spreading of antibiotic resistance, and associated costs. Data from recent comparative trials has shown that 1-2 weeks is sufficient for most soft tissue infections, and 4 to 6 weeks appears adequate in those with (unresected) infected bone. Retrospective reviews over the past two decades have demonstrated that about two-thirds of selected patients with diabetic foot osteomyelitis can achieve remission with antibiotic therapy alone (i.e., without bone resection). One recent randomized trial found that treatment with only antibiotic therapy (given for 90 days) gave similar clinical outcomes to treatment with conservative surgery (removal only of the infected bone) along with just a short course of antibiotic therapy. Another randomized trial compared a 6-week against 12-week course of antibiotic therapy, without concomitant surgery, for diabetic foot osteomyelitis and also found similar outcomes. Likewise, the optimal antibiotic duration for any skin and soft tissue infection is unknown. According to some databases of University of Geneva Hospitals, among 378 skin and soft tissue infections in 346, overall cure was achieved in 330 episodes (87%) after a median antibiotic administration of 15 days. In multivariate Cox regression analysis, duration of antibiotic therapy (HR 1.0, 95%CI 0.96-1.02) did not influence treatment failure among patients with positive MRSA carriage. Our study intends to optimize the duration of antibiotic therapy in DFI; for skin and soft tissue infections as well as for diabetic toe osteomyelitis that is not amputated.
Interventions
Surgical debridement
Microbiological sampling
Revascularisation (if needed).
Off-loading by Special shoes
Patient's education and instructions by specialized nurses
Regular wound debridement by specialized nurses
Systemic antibiotic duration according to the study arms
Sponsors
Study design
Intervention model description
Two prospected-randomized protocols
Eligibility
Inclusion criteria
1. Age ≥ 18 2. Diabetes mellitus 3. Diabetic Foot Infections 4. Surgical intervention to remove all necrotic tissue or tenotomy. 5. Osteomyelitis limited to bone contact or cortical lesions in X-ray.
Exclusion criteria
1. Implanted device. 2. More than 96 hours of systemic antibiotic therapy prior to inclusion 3. Amputation 4. Destructive osteomyelitis 5. Concomitant infections requiring more than 14 days of antibiotic therapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Experiencing Clinical Failure | 30-60 days | Visual and dichotomous evaluation regarding the numbers of clinical recurrence/failure |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Experiencing Adverse Events Related to the Antibiotic Therapy | 30-60 days | Adverse events related to the antibiotic therapy. |
Countries
Switzerland
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Short Antibiotic Arm 10 days for soft tissue infections 3 weeks for osteomyelitis
Surgical debridement (if needed): Surgical debridement
Microbiological sampling: Microbiological sampling
Revascularisation (if needed).: Revascularisation (if needed).
Off-loading: Off-loading by Special shoes
Patient's education and instructions: Patient's education and instructions by specialized nurses
Wound debridement: Regular wound debridement by specialized nurses
Antibiotic duration: Systemic antibiotic duration according to the study arms | 79 |
| Standard Antibiotic Arm 20 days for soft tissue infections 6 weeks for osteomyelitis
Surgical debridement (if needed): Surgical debridement
Microbiological sampling: Microbiological sampling
Revascularisation (if needed).: Revascularisation (if needed).
Off-loading: Off-loading by Special shoes
Patient's education and instructions: Patient's education and instructions by specialized nurses
Wound debridement: Regular wound debridement by specialized nurses
Antibiotic duration: Systemic antibiotic duration according to the study arms | 80 |
| Total | 159 |
Baseline characteristics
| Characteristic | Total | Standard Antibiotic Arm | Short Antibiotic Arm |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 94 Participants | 42 Participants | 52 Participants |
| Age, Categorical Between 18 and 65 years | 65 Participants | 38 Participants | 27 Participants |
| Age, Continuous | 68 years | 67 years | 70 years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 159 Participants | 80 Participants | 79 Participants |
| Region of Enrollment Switzerland | 159 participants | 80 participants | 79 participants |
| Sex: Female, Male Female | 17 Participants | 8 Participants | 9 Participants |
| Sex: Female, Male Male | 142 Participants | 72 Participants | 70 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 79 | 0 / 80 |
| other Total, other adverse events | 5 / 79 | 6 / 80 |
| serious Total, serious adverse events | 5 / 79 | 6 / 80 |
Outcome results
Number of Participants Experiencing Clinical Failure
Visual and dichotomous evaluation regarding the numbers of clinical recurrence/failure
Time frame: 30-60 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Short Antibiotic Arm | Number of Participants Experiencing Clinical Failure | 26 Participants |
| Long Antibiotic Arm | Number of Participants Experiencing Clinical Failure | 30 Participants |
Number of Participants Experiencing Adverse Events Related to the Antibiotic Therapy
Adverse events related to the antibiotic therapy.
Time frame: 30-60 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Short Antibiotic Arm | Number of Participants Experiencing Adverse Events Related to the Antibiotic Therapy | 31 Participants |
| Long Antibiotic Arm | Number of Participants Experiencing Adverse Events Related to the Antibiotic Therapy | 27 Participants |